In vivo, light-activated CX-5461 suppresses tumor growth and extends survival in immunocompetent syngeneic models, eliciting hallmarks consistent with immunogenic genome stress, and supporting a model in which broader oxidative DNA damage may also contribute to the biological response.
Abstract
Abstract CX-5461 (pidnarulex) is the most clinically advanced small-molecule ligand associated with G-quadruplex (G4) targeting and shows activity in DNA repair–deficient tumors, yet its clinical use is associated with dose-limiting phototoxicity. Here, we repurpose this intrinsic photoreactivity to investigate CX-5461 as a G4-associated, light-activated antitumor scaffold. In solution, CX-5461 produces both Type I and Type II reactive oxygen species (ROS), whereas complexation with G4 DNA markedly decreases detectable singlet oxygen (1O2) formation and favors radical-associated Type I oxidation. This G4-modulated photochemical shift drives oxidative remodeling and destabilization of G4-containing DNA. In cancer cells, photoactivation enhances cytotoxicity by up to two orders of magnitude relative to the dark state and is accompanied by elevated intracellular ROS, increased 8-oxoG formation, γ-H2AX accumulation, and changes in BG4-detected nuclear G4 structures. In vivo, light-activated CX-5461 suppresses tumor growth and extends survival in immunocompetent syngeneic models, eliciting hallmarks consistent with immunogenic genome stress. Collectively, these findings reposition CX-5461 as a clinically relevant scaffold for G4-associated photogenomic cancer therapy, while supporting a model in which broader oxidative DNA damage may also contribute to the biological response.
Cisplatin-based chemotherapy remains a cornerstone in cancer treatment, yet its clinical utility is often hampered by severe systemic toxicity and the cold immune microenvironment of many tumors. To address these challenges, we leveraged the kinetically inert nature and structural versatility of the Platinum (IV) [Pt (...
Jun-Kang Ren, Jia-Ni Wu, Xin-Yu Dai et al.· European journal of medicina...· 0 citations
Mitochondria are emerging as critical hubs for cancer therapeutics, yet the development of agents that simultaneously enable real-time imaging and targeted therapy remains a formidable challenge. Here we report LN1, a smart theranostic small molecule designed to selectively target mitochondrial G-quadruplex (mtG4) DNA...
Nuan Li, Wen-Bo Yan, Zhe Wang et al.· Spectrochimica Acta Part A -...· 0 citations
G-Quadruplexes are non-canonical nucleic acid structures mostly located in gene promoters and telomeres. Although G4 stabilization with synthetic/natural ligands is a promising anticancer approach, dense distribution throughout the genome restricts their selective targeting. Additionally, cationic G4 ligands are wide...
We report a structure-activity relationship of merocyanine quinolinium dyes optimized as fluorogenic rRNA-associated probes. A series of analogs (11a-h) bearing electron-withdrawing groups (EWGs) or electron-donating groups (EDGs) on the phenolic "push" ring (ortho vs meta; mono vs disubstitution) was synthesized to ev...
Devorah Corn, Alon Boocholez, Prasenjit Das et al.· Journal of Medicinal Chemist...· 0 citations
This work supports mtDNA G4-associated recognition as a strategy for improving the subcellular precision of PDT and provides a generalizable framework for developing mitochondria-directed phototherapies.
It is demonstrated that CX-5461 appears as highly potent G4-ligand inducing p53-dependent molecular cascades leading to cell death in germ cell tumors.
Rashidul Islam, Annalena Liesen, C. S. R. Roque et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.